Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EnteroMedics Eyes First Commercial Maestro Implants For Obesity After Months Of Prep

This article was originally published in The Gray Sheet

Executive Summary

The company says its training and facility certification efforts are on track to support commercial implants by June. The next challenge will be gaining broad-based reimbursement, as the first procedures are expected to be funded by self-pay or one-off local coverage.

You may also be interested in...



Preferential Treatment: US FDA Asks Patients For Their Input

As the agency continues to incorporate more patient-preference data into its regulatory process, it is asking stakeholders on the kinds of diseases and other factors it should consider when evaluating patient-preference information. The feedback is ultimately meant to inform regulators and sponsors about what patients want as they develop products.

Expanding The Medtech Toolbox: US FDA's 'Medical Device Development Tools' Program Rolls Out

Three years in the making, FDA has released a final guidance for medical device development tools that would allow developers to qualify their MDDTs and give medical device manufactures access to new tools that could help them prove safety and effectiveness of their products sooner.

US Neurostimulation Devices Market Forecast to Grow By $1B+ With New Indications, New Technologies

The US neurostimulation technology market will grow nearly 46% over the next five years, according to a new report from Medtech Insight.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT033791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel